Avadel Pharmaceuticals plc

NasdaqGM AVDL

Avadel Pharmaceuticals plc Total Assets for the year ending December 31, 2023: USD 164.70 M

Avadel Pharmaceuticals plc Total Assets is USD 164.70 M for the year ending December 31, 2023, a 24.03% change year over year. Total assets are the total value of all assets owned by a company, representing its resources.

Avadel Pharmaceuticals plc Total Assets for the year ending December 31, 2022 was USD 132.78 M, a -46.30% change year over year.
Avadel Pharmaceuticals plc Total Assets for the year ending December 31, 2021 was USD 247.26 M, a -20.66% change year over year.
Avadel Pharmaceuticals plc Total Assets for the year ending December 31, 2020 was USD 311.64 M, a 105.79% change year over year.
Avadel Pharmaceuticals plc Total Assets for the year ending December 31, 2019 was USD 151.44 M, a -20.42% change year over year.

Key data

Date	Total Assets	Current Liabilities	Total Non-Current Liabilities	Shareholders' Equity

NasdaqGM: AVDL

Avadel Pharmaceuticals plc

CEO	Mr. Gregory J. Divis Jr.
IPO Date	June 7, 1996
Location	Ireland
Headquarters	10 Earlsfort Terrace
Employees	154
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Key trends

Past 5 years